Mohammad Alzrigat

472 total citations
15 papers, 317 citations indexed

About

Mohammad Alzrigat is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Mohammad Alzrigat has authored 15 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Oncology. Recurrent topics in Mohammad Alzrigat's work include Histone Deacetylase Inhibitors Research (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Protein Degradation and Inhibitors (5 papers). Mohammad Alzrigat is often cited by papers focused on Histone Deacetylase Inhibitors Research (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Protein Degradation and Inhibitors (5 papers). Mohammad Alzrigat collaborates with scholars based in Sweden, United States and Canada. Mohammad Alzrigat's co-authors include Helena Jernberg‐Wiklund, Anqi Ma, Fredrik Öberg, Jian Jin, Antonia Kalushkova, Kenneth Nilsson, Prasoon Agarwal, Anders Österborg, Jonathan D. Licht and Thomas Stamminger and has published in prestigious journals such as Nature Communications, The Journal of Cell Biology and International Journal of Molecular Sciences.

In The Last Decade

Mohammad Alzrigat

14 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohammad Alzrigat Sweden 9 260 122 60 42 42 15 317
Matthew D. Witkin United States 6 286 1.1× 109 0.9× 43 0.7× 81 1.9× 47 1.1× 8 365
Jeffrey Strovel United States 11 264 1.0× 97 0.8× 28 0.5× 61 1.5× 20 0.5× 24 340
Haiming Xu United States 9 523 2.0× 248 2.0× 45 0.8× 42 1.0× 46 1.1× 19 604
Gue Su Chang United States 8 196 0.8× 120 1.0× 47 0.8× 41 1.0× 31 0.7× 13 288
Marta Tapia United Kingdom 10 310 1.2× 121 1.0× 40 0.7× 27 0.6× 30 0.7× 13 366
Jiro Minami Japan 9 144 0.6× 103 0.8× 28 0.5× 68 1.6× 40 1.0× 21 266
Samuel Gusscott Canada 8 210 0.8× 92 0.8× 98 1.6× 62 1.5× 45 1.1× 16 345
Fabio M. R. Amaral United Kingdom 8 228 0.9× 82 0.7× 28 0.5× 38 0.9× 31 0.7× 19 273
Jutta Ortiz-Tánchez Germany 6 157 0.6× 86 0.7× 33 0.6× 40 1.0× 38 0.9× 8 245
Ali Aghajanirefah Netherlands 7 221 0.8× 109 0.9× 46 0.8× 34 0.8× 49 1.2× 11 366

Countries citing papers authored by Mohammad Alzrigat

Since Specialization
Citations

This map shows the geographic impact of Mohammad Alzrigat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Alzrigat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Alzrigat more than expected).

Fields of papers citing papers by Mohammad Alzrigat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammad Alzrigat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Alzrigat. The network helps show where Mohammad Alzrigat may publish in the future.

Co-authorship network of co-authors of Mohammad Alzrigat

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Alzrigat. A scholar is included among the top collaborators of Mohammad Alzrigat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Alzrigat. Mohammad Alzrigat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Liu, Ruining, Radosveta Gencheva, Zhen Gong, et al.. (2025). The inhibition of TXNRD1 by methylglyoxal impairs the intracellular control of Mycobacterium tuberculosis. Redox Biology. 85. 103741–103741.
2.
Cerrato, Carmine Pasquale, Judit Liaño-Pons, Mohammad Alzrigat, et al.. (2025). Engineered Peptide Coacervates Enable Efficient Intracellular Delivery of the MYC Inhibitor omoMYC. Molecular Pharmaceutics. 22(6). 3479–3490. 3 indexed citations
3.
Liaño-Pons, Judit, Jiansheng Wang, Mohammad Alzrigat, et al.. (2024). EZH2 inhibition sensitizes retinoic acid-driven senescence in synovial sarcoma. Cell Death and Disease. 15(11). 836–836. 1 indexed citations
4.
Yuan, Ye, Mohammad Alzrigat, Xueyao Wang, et al.. (2023). Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development. Cancers. 15(18). 4599–4599. 4 indexed citations
5.
Agarwal, Prasoon, et al.. (2023). MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma. International Journal of Molecular Sciences. 24(9). 8141–8141. 5 indexed citations
6.
Liu, Ruining, Wenjun Mou, Juan Yuan, et al.. (2022). HIF-1 stabilization in T cells hampers the control of Mycobacterium tuberculosis infection. Nature Communications. 13(1). 5093–5093. 15 indexed citations
7.
Zhang, Fan, et al.. (2021). Methods to Study Myc-Regulated Cellular Senescence: An Update. Methods in molecular biology. 2318. 241–254. 5 indexed citations
8.
Bocci, Matteo, Vedrana Tabor, Per Hydbring, et al.. (2020). Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence. Cell Cycle. 20(1). 23–38. 9 indexed citations
9.
Alzrigat, Mohammad, Helena Jernberg‐Wiklund, & Jonathan D. Licht. (2018). Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity. Epigenomes. 2(3). 16–16. 18 indexed citations
10.
Alzrigat, Mohammad, et al.. (2017). Epigenetics in multiple myeloma: From mechanisms to therapy. Seminars in Cancer Biology. 51. 101–115. 66 indexed citations
11.
12.
Alzrigat, Mohammad, Muntasir Mamun Majumder, Anqi Ma, et al.. (2017). The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget. 8(61). 103731–103743. 17 indexed citations
13.
Alzrigat, Mohammad, Prasoon Agarwal, Hadil Zureigat, et al.. (2016). EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget. 8(6). 10213–10224. 46 indexed citations
14.
15.
Alzrigat, Mohammad, Nina Reuter, Anna von Mikecz, et al.. (2012). PML promotes MHC class II gene expression by stabilizing the class II transactivator. The Journal of Cell Biology. 199(1). 49–63. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew D. Witkin Breakdown of academic impact, for papers by Jeffrey Strovel Breakdown of academic impact, for papers by Haiming Xu Breakdown of academic impact, for papers by Gue Su Chang Breakdown of academic impact, for papers by Marta Tapia Breakdown of academic impact, for papers by Jiro Minami Breakdown of academic impact, for papers by Samuel Gusscott Breakdown of academic impact, for papers by Fabio M. R. Amaral Breakdown of academic impact, for papers by Jutta Ortiz-Tánchez Breakdown of academic impact, for papers by Ali Aghajanirefah
Rankless by CCL
2026